

1. NAME OF THE MEDICINAL PRODUCT

Hizentra

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Immunoglobulin normal Human (SCIg)

One ml contains:

Human normal immunoglobulin200 mg
(purity: at least 98% is immunoglobulin type G (IgG))

Vials

Each vial of 5 ml solution contains: 1 g of human normal immunoglobulin

Each vial of 10 ml solution contains: 2 g of human normal immunoglobulin

Each vial of 20 ml solution contains: 4 g of human normal immunoglobulin

Each vial of 50 ml solution contains: 10 g of human normal immunoglobulin

Pre-filled syringes

Each pre-filled syringe of 5 ml solution contains: 1 g human normal immunoglobulin

Each pre-filled syringe of 10 ml solution contains: 2 g human normal immunoglobulin

Distribution of the IgG subclasses (approx. values):

IgG1 69 %

IgG2 26 %

IgG3 3 %

IgG4 2 %

The maximum IgA content is 50 micrograms/ml.

Produced from the plasma of human donors.

Excipients with known effects

Hizentra contains approximately 250 mmol/L of L-proline.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Solution for subcutaneous infusion.

The solution is clear and pale-yellow or light-brown.

Hizentra has an approximate osmolality of 380 mOsmol/kg.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Replacement therapy in adults and children in primary immunodeficiency syndromes such as:

- congenital agammaglobulinaemia and hypogammaglobulinaemia
- common variable immunodeficiency
- severe combined immunodeficiency and Wiskott-Aldrich syndrome
- IgG subclass deficiencies with recurrent infections

Replacement therapy in myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.

4.2 Posology and method of administration

Posology for adults and children

The dose may need to be individualised for each patient dependent on the pharmacokinetic and clinical response and serum IgG trough levels. The following dose regimens are given as a guideline.

The dose regimen using the subcutaneous route should achieve a sustained level of IgG. A loading dose of at least 0.2 to 0.5 g/kg (1.0 to 2.5 ml/kg) body weight may be required. This may need to be divided over several days. After steady state IgG levels have been attained, maintenance doses are divided into smaller doses and administered at repeated intervals to reach a cumulative monthly dose in the order of 0.4 to 0.8 g/kg (2.0 - 4.0 ml/kg) body weight (see section "Pharmacokinetics").

For patients switching from intravenous to subcutaneous treatment the monthly dose is divided into smaller doses and administered at repeated intervals (see section "Pharmacokinetics").

Trough levels should be measured and assessed in conjunction with the patient's clinical response. Depending on the clinical response (e.g. infection rate), adjustment of the dose and/or the dose interval may be considered in order to aim for higher trough levels.

Posology for children and adolescents

The posology is given by body weight like in adults.

Hizentra was evaluated in 21 children aged 2 to 11 years and 12 adolescents aged 12 to 16 years in two clinical studies.

Method of administration

Hizentra must be administered via the subcutaneous route only.

Hizentra may be injected into sites such as abdomen, thigh, upper arm, and lateral hip (see figure 1).




Figure 1: Possible infusion sites for Hizentra

If large doses are given (>25 ml), it is advisable to administer them at multiple sites. Up to 4 infusion sites can be used simultaneously.

Infusion for home treatment should be commenced and initially supervised and monitored by a healthcare professional. The healthcare professional should already be experienced in the guidance of home treatment of patients with primary immunodeficiency syndromes. The patient must be instructed in the using an infusion pump, infusion techniques, the keeping of treatment diary, recognition of and measures to be taken in case of severe adverse reactions.

Infusion rate

The recommended initial infusion rate depends on individual needs of the patient and should not exceed 15 ml/hour/site.

If well-tolerated, the infusion rate can then gradually be increased to 25 ml/hour/site.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see section 4.4).

Patients with hyperprolinaemia type I or II.

Hizentra must not be given intravascularly.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hizentra is for subcutaneous use only. If Hizentra is accidentally administered into a blood vessel, patients could develop shock.

The recommended infusion rate given under section 4.2 should be adhered to. Patients should be closely monitored and carefully observed for any adverse events throughout the infusion period.

Certain adverse reactions may occur more frequently in patients who receive human normal immunoglobulin for the first time or, in rare cases, when the human normal immunoglobulin product is switched or when treatment has been stopped for more than eight weeks.

Potential complications can often be avoided by ensuring that patients:

- are not sensitive to human normal immunoglobulin, by initially injecting the product slowly (see section 4.2);
- are carefully monitored for any symptoms throughout the infusion period. In particular, patients naïve to human normal immunoglobulin, patients switched from an alternative product or when there has been a long interval since the previous infusion should be monitored during the first infusion and for the first hour after the first infusion, in order to detect potential adverse reactions.

All other patients should be observed for at least 20 minutes after administration.

Suspicion of allergic or anaphylactic type reactions requires immediate discontinuation of the infusion. In case of shock, standard medical treatment should be administered.

Hypersensitivity

True allergic reactions are rare. They can particularly occur in patients with anti-IgA antibodies who should be treated with particular caution. Patients with anti-IgA antibodies, in whom treatment with subcutaneous IgG products remains the only option, should be switched to Hizentra only under close medical supervision.

Rarely, human normal immunoglobulin can induce a fall in blood pressure with anaphylactic reaction, even in patients who had tolerated previous treatment with human normal immunoglobulin.

Thromboembolism

Arterial and venous thromboembolic events including myocardial infarction, stroke, deep venous thrombosis and pulmonary embolism have been associated with the use of immunoglobulins. Caution should be exercised in patients with pre-existing risk factors for thrombotic events (such as advanced age, hypertension, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, patients with prolonged periods of immobilization, severely hypovolemic patients, patients with diseases which increase blood viscosity). Patients should be informed about first symptoms of thromboembolic events including shortness of breath, pain and swelling of a limb, focal neurological deficits and chest pain and should be advised to contact their physician immediately upon onset of symptoms. Patients should be sufficiently hydrated before use of immunoglobulins.

Aseptic Meningitis Syndrome (AMS)

AMS has been reported with use of IVIg or SCIg. The syndrome usually begins within several hours to 2 days following immune globulin treatment. AMS is characterised by the following signs and symptoms: severe headache, neck stiffness, drowsiness, fever, photophobia, nausea, and vomiting. Patients exhibiting signs and symptoms of AMS should receive a thorough neurological examination, including CSF studies, to rule out other causes of meningitis. Discontinuation of immunoglobulin treatment may result in remission of AMS within several days without sequelae.

Information on safety with respect to transmissible agents

Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.

The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV and for the non-enveloped viruses HAV and parvovirus B19.

There is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to the viral safety.

Interference with serological testing

After infusion of immunoglobulin the transitory rise of the various passively transferred antibodies in the patient's blood may result in misleading positive results in serological testing.

Passive transmission of antibodies to erythrocyte antigens, e.g. A, B, D may interfere with some serological tests for red cell allo-antibodies (Coombs' test).

Sodium content

Hizentra is essentially sodium free.

Paediatric population

The same warnings and precautions apply to the paediatric population.

Elderly population

The same warnings and precautions apply to the elderly population.

4.5 Interactions with other medicinal products and other forms of interaction

Live attenuated virus vaccines

Immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella. After administration of this medicinal product, an interval of 3 months should elapse before vaccination with live attenuated virus vaccines. In the case of measles, this impairment may persist for up to 1 year. Therefore patients receiving measles vaccine should have their antibody status checked.

Paediatric population

The same interactions may occur in the paediatric population.

Elderly population

The same interactions may occur in the elderly population.

4.6 Fertility, pregnancy and lactation

Pregnancy

Data from prospective clinical trials on the use of human normal immunoglobulin in pregnant women is limited. Therefore, Hizentra should only be given with caution to pregnant women. Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus or the neonate are to be expected.

Continued treatment of the pregnant woman ensures a passive immunity for the neonate.

Breast-feeding

Data from prospective clinical trials on the use of human normal immunoglobulin in breast feeding women is limited. Therefore, Hizentra should only be given with caution to breast-feeding mothers. Clinical experience with immunoglobulins suggests however that no harmful effects on the neonate are to be expected.

Immunoglobulins are excreted into the milk and may contribute to the transfer of protective antibodies to the neonate.

Fertility

Clinical experience with immunoglobulins suggests that no harmful effects on fertility are to be expected.

4.7 Effects on ability to drive and use machines

The ability to drive and operate machines may be impaired by some adverse reactions associated with Hizentra. Patients who experience adverse reactions during treatment should wait for these to resolve before driving or operating machines.

4.8 Undesirable effects

Summary of safety profile

Adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.

Rarely human normal immunoglobulins may cause a sudden fall in blood pressure and in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity to previous administration.

Local reactions at infusion sites: swelling, soreness, redness, induration, local heat, itching, bruising and rash.

For safety with respect to transmissible agents, see section 4.4.

Tabulated list of adverse reactions

Adverse Reactions (ARs) have been collected in Hizentra clinical trials from 8 phase III studies ,1 extension study, and 2 phase IV studies in a total of 502 patients. The ADRs reported in these clinical studies are summarised and categorised according to the MedDRA System Organ Class (SOC and Preferred Term level) and frequency below.

Frequency per patient or per infusion has been evaluated using the following criteria: Very common ($\geq 1/10$), Common ($\geq 1/100$ to $< 1/10$), Uncommon ($\geq 1/1,000$ to $< 1/100$), Rare ($\geq 1/10,000$ to $< 1/1,000$), Very rare ($< 1/10,000$). For spontaneous post-marketing ADRs, the reporting frequency is categorised as unknown.

Frequency of Adverse Drug Reactions (ADR) associated with Hizentra obtained from clinical studies and post-marketing surveillance, reporting rate per patient or per infusion

System Organ Class (SOC, MedDRA)	ADRs (MedDRA Preferred Term, PT)	ADR frequency category per patient	ADR frequency category per infusion
Immune system disorders	Hypersensitivity	Uncommon	Rare
	Anaphylactic reaction	Unknown	Unknown
Nervous system disorders	Headache	Very common	Uncommon
	Dizziness, Migraine	Common	Rare
	Tremor (including Psychomotor hyperactivity)	Uncommon	Rare
	Meningitis aseptic	Uncommon	Very rare
	Burning sensation	Unknown	Unknown
Cardiac disorders	Tachycardia	Uncommon	Very rare

System Organ Class (SOC, MedDRA)	ADRs (MedDRA Preferred Term, PT)	ADR frequency category per patient	ADR frequency category per infusion
Vascular disorders	Hypertension	Common	Rare
	Flushing	Uncommon	Rare
	Embolic and thrombotic events	Unknown	Unknown
Gastrointestinal disorders	Diarrhoea, abdominal pain	Common	Uncommon
	Nausea, Vomiting	Common	Rare
Skin and subcutaneous tissue disorders	Rash	Very common	Uncommon
	Pruritus, urticaria	Common	Rare
Musculoskeletal and connective tissue disorders	Musculoskeletal pain, Arthralgia	Common	Uncommon
	Muscle spasm, Muscular weakness	Uncommon	Rare
General disorders and administration site conditions	Infusion site reactions	Very common	Very common
	Fatigue (including malaise), Pyrexia	Common	Uncommon
	Chest pain, Influenza like illness, Pain	Common	Rare
	Chills (including hypothermia)	Uncommon	Rare
	Infusion site ulcer	Unknown	Unknown
Investigations	Blood creatinine increased	Uncommon	Rare

Paediatric population

Clinical trials with Hizentra showed a similar overall safety profile in paediatric and adult patients with PID.

Elderly population

The same adverse reactions may occur in the elderly population. Information available from clinical trials showed no difference in the safety profile of patients ≥ 65 years of age than of younger patients.

Postmarketing experience with Hizentra in patients ≥ 65 years of age shows an overall similar safety profile in this age group as in younger patients.

Please refer to section 4.4 for details on risk factors and monitoring recommendations.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form

<https://sideeffects.health.gov.il/>

and emailed to the Registration Holder's Patient Safety Unit at:

drugsafety@neopharmgroup.com

4.9 Overdose

Consequences of an overdose are not known.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: immune sera and immunoglobulins: immunoglobulins, normal human, for extravascular administration, ATC code: J06BA01.

Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents.

Human normal immunoglobulin contains the IgG antibodies present in the normal population. It is usually prepared from pooled plasma from not fewer than 1,000 donors. It has a distribution of immunoglobulin G subclasses closely proportional to that in native human plasma.

Mechanism of action

In immunodeficiency, adequate doses of Hizentra may restore abnormally low immunoglobulin G antibody levels to the normal range and thus help against infections.

PID

In the European pivotal prospective open label, single arm and multicentre study, a total of 51 subjects with primary immunodeficiency syndromes aged between 3 and 60 years old were treated with Hizentra for up to 41 weeks. The mean dose administered each week was 0.12 g/kg body weight (bw). Sustained IgG trough levels with mean concentrations of 7.99 – 8.25 g/l were thereby achieved throughout the treatment period. Subjects received in total 1,831 weekly Hizentra infusions.

In the US prospective open label, single arm and multicentre study, a total of 49 subjects with primary immunodeficiency syndromes aged between 5 and 72 years old were treated with Hizentra for up to 15 months. The mean dose administered each week was 0.23 g/kg bw. Sustained IgG trough levels with a mean concentration of 12.53 g/l were thereby achieved throughout the treatment period. Subjects received in total 2,264 weekly Hizentra infusions.

No serious bacterial infections were reported during the efficacy period in subjects receiving Hizentra during clinical studies.

To assess the safety and tolerability of higher infusion rates applied via the manual push and pump-assisted administration, 49 PID subjects aged 2 to 75 years were enrolled in an open-label, multicentre, parallel-arm, nonrandomised phase IV HILO (Hizentra Label Optimization) study and treated with Hizentra for at least 12 weeks (11 paediatric patients aged 2 to <18, 35 adult patients aged 18 to 65, and 3 geriatric patients aged >65 years). In the first patient group receiving Hizentra via the manual push technique (n=16), 2 to 7 infusions per week were administered with the flow rates of 30, 60 and 120 ml/hour/site (see section 4.2). In the second patient group receiving Hizentra via pump-assisted administration (n=18), weekly Hizentra infusions were administered with 25, 50, 75 and 100 ml/hour/site flow rate. In a third group, infusion volumes of 25, 40 and 50ml per site were additionally evaluated in pump-assisted administration of weekly Hizentra doses (n=15). In all three groups, each infusion parameter was used for 4 weeks, after which subjects successfully completing required minimal number of valid infusions could switch to the next higher infusion parameter.

The primary endpoint was the percentage of subjects responding to a higher infusion parameter:

Group	Infusion parameter and responder rate (%)			
	30 ml/hour/site	60 ml/hour/site	120 ml/hour/site	-
1. manual push flow rates	100.0 %	100.0 %	87.5 %	-
2. pump-assisted flow rates	77.8 %	77.8 %	66.7 %	61.1 %
3. pump-assisted volumes	86.7 %	73.3 %	73.3 %	-

Responder: in the pump-assisted group a subject who performed ≥ 3 valid infusions out of 4 for an infusion parameter; in the manual push group a subject who performed ≥ 60 % of valid infusions for an infusion parameter. An infusion was considered valid, if ≥ 95 % of the planned flow rate/volume per ≥ 1 infusion site was achieved.

Overall, the number of infusions without severe local reactions versus the total number of infusions (tolerability) was ≥ 0.98 in all groups for all infusion parameters. No clinically relevant differences in the serum IgG trough concentrations were observed between the baseline at day 1 and the end of the study in all subjects.

Paediatric population

The safety and effectiveness of Hizentra have been established in paediatric subjects 2 to 18 years of age. Hizentra was evaluated in 68 paediatric subjects with PID 2 to <12 years of age and in 57 paediatric subjects 12 to <18 years of age. There were no differences in the pharmacokinetics, safety and efficacy profiles as compared with adult subjects. No paediatric-specific dose adjustments were necessary to achieve the desired serum IgG levels. No differences were seen in the pharmacodynamic properties between adult and paediatric study patients with PID.

Elderly population

No overall differences in safety or efficacy were observed between PID subjects >65 years and PID subjects 18 to 65 years of age. In the clinical studies Hizentra was evaluated in 13 patients with PID >65 years of age.

5.2 Pharmacokinetic properties

Absorption and Distribution

Following subcutaneous administration of Hizentra, peak serum levels are achieved after approximately 2 days.

Elimination

IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.

PID

In a clinical phase III trial with Hizentra (n = 46), the subjects achieved sustained trough levels (median 8.1 g/l) over a period of 29 weeks when receiving median weekly doses of 0.06 to 0.24 g/kgbw.

Simulations by empirical Population Pharmacokinetic models suggested that comparable IgG exposure levels ($AUC_{0-14days}$, $C_{min 14days}$) may be obtained if Hizentra is administered subcutaneously every two weeks using double the weekly dose during maintenance therapy.

These simulations further suggested that comparable serum IgG trough levels can be achieved when the weekly maintenance dose of Hizentra is administered in proportional amounts more frequently than once a week (e.g. 2 times per week, 3 times per week, 5 times per week or daily).

Simulation of 2-3 missed daily doses resulted in a median serum IgG level decrease of $\leq 4\%$ compared to consistent daily dosing. By replacing the missed doses when daily dosing was resumed, the median concentration profile recovered within 2 to 3 days. However, if missed doses were not replaced when dosing was resumed, it took up to 5-6 weeks for the IgG trough levels to return to steady-state.

Paediatric population

No differences were seen in the pharmacokinetic parameters between adult and paediatric PID study patients.

Elderly population

No overall differences in the pharmacokinetic parameters were observed between PID subjects >65 years and subjects 18 to 65 years of age.

5.3 Preclinical safety data

Immunoglobulins are a normal constituent of the human body. L-proline is a physiological, non-essential amino acid.

The safety of Hizentra has been assessed in several preclinical studies, with particular reference to the excipient L-proline. Non-clinical data reveal no special risk for humans based on safety pharmacology and toxicity studies.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

L-proline
Polysorbate 80
Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

The expiry date of the product is indicated on the packaging materials.
Once a vial or the blistered pre-filled syringe has been opened, the solution should be used immediately.

6.4 Special precautions for storage

Do not store above 25 °C.
Do not freeze.
Keep the vial or the blistered pre-filled syringe in the outer carton in order to protect from light.

For storage conditions after first opening of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Vials

5, 10 or 20 ml of solution in a vial (type I glass) and 50 ml of solution in a vial (type II glass), with a stopper (halobutyl), a cap (aluminium crimp) and a flip off disc (plastic).

Pack sizes of 1 vial:

- 1 g / 5 ml
- 2 g / 10 ml
- 4 g / 20 ml
- 10 g / 50 ml

Pre-filled syringes

5, or 10 ml of solution in a pre-filled syringe (cyclo-olefin-copolymer (COC)).

Pack sizes of 1 pre-filled syringe:

- 1 g / 5 ml
- 2 g / 10 ml

Alcohol swabs, needles and other supplies or equipment are not contained in the pack.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Hizentra comes as a ready-to-use solution in single-use vials or single-use pre-filled syringes. Because the solution contains no preservative, Hizentra should be used/infused as soon as possible after opening the vial or blistered pre-filled syringe.

The medicinal product should be brought to room or body temperature before use.

The solution should be clear and pale-yellow or light-brown.
Solutions that are cloudy or have deposits should not be used.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MANUFACTURER

CSL Behring AG
Wankdorfstrasse 10
CH-3014 Bern, Switzerland

8. REGISTRATION HOLDER

Genmedix
12 Beit Harishonim Street, Emek-Hefer Industrial Park
Israel



9. REGISTRATION NUMBER

164-52-35308-00

Approved on May 2020